[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584776":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":54,"collaborators":56,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":10,"enrollmentInfo":90,"targetDuration":93,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"No Intervention",null,"People starting treatment for tuberculosis disease",[13],{"name":14,"affiliation":15,"role":16},"Nathalie DE CASTRO, MD PHD","Hôpital Saint Louis Paris","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Olivier MARCY, MD PHD","CONTACT","+33 5 57 57 17 67","olivier.marcy@u-bordeaux.fr",[24,42],{"facility":25,"status":26,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"AP-HP Hôpital Saint Louis - Service des Maladies Infectieuses et Tropicales","NOT_YET_RECRUITING","Paris","75010","France","FR",{"type":32,"coordinates":33},"Point",[34,35],2.3488,48.85341,{"lat":35,"lon":34},[38],{"name":39,"role":20,"phone":40,"phoneExt":10,"email":41},"Nathalie DE CASTRO, Dr","+33 (0)1 42 49 45 72","nathalie.de-castro@aphp.fr",{"facility":43,"status":44,"city":45,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Service de pneumologie et maladies infectieuses, Centre hospitalier Delafontaine","RECRUITING","Saint-Denis",{"type":32,"coordinates":47},[48,49],2.35387,48.93564,{"lat":49,"lon":48},[52],{"name":53,"role":20,"phone":10,"phoneExt":10,"email":10},"Yacine Tandjaoui-Lambiotte Tandjaoui-Lambiotte, Dr",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[57,60,62,64,66,68,70,72,74,76,78],{"name":58,"class":59},"University of Bordeaux","OTHER",{"name":61,"class":59},"Amiens University Hospital",{"name":63,"class":59},"Centre National de la Recherche Scientifique, France",{"name":65,"class":59},"Saint Antoine University Hospital",{"name":67,"class":59},"University of Lyon",{"name":69,"class":59},"Claude Bernard University",{"name":71,"class":59},"University Hospital, Bordeaux",{"name":73,"class":59},"Saint-Louis Hospital, Paris, France",{"name":75,"class":59},"Centre Hospitalier Universitaire, Amiens",{"name":77,"class":59},"Hôpital Jean Verdier",{"name":79,"class":6},"Institut National de la Santé Et de la Recherche Médicale, France","100584776","prospective-cohort-of-people-starting-treatment-for-tuberculosis-disease-in-france-frenchtb-100584776",false,"NCT06893757","Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)","Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France - ANRS 464s FrenchTB","FrenchTB","Inclusion Criteria:\n\n* Aged ≥18 years.\n* Diagnosis of tuberculosis by microbiological or clinical means, including on the basis of a pathological examination for extrapulmonary tuberculosis leading to a Compulsory Declaration (CD) and treated for less than 8 days.\n* Have signed a voluntary, informed and written consent (at the latest on the day of inclusion and before any examination carried out as part of the research), or alternatively, consent from relatives in cases of tuberculous meningitis or other serious forms of tuberculosis with impaired consciousness or confusion, until the person is able to give their consent.\n\nExclusion Criteria:\n\n* Presence of significant cognitive impairment that, in the opinion of the site investigator or designated person, may affect the ability to give reliable informed consent (except in the specific case of meningeal tuberculosis).","ALL","18 Years",{"count":91,"type":92},2000,"ESTIMATED","5 Years","OBSERVATIONAL","The French Tuberculosis Cohort is a prospective, national, multicenter, low-intervention study including subjects aged 18 years and older with tuberculosis disease for which inpatient treatment is initiated. The goal of this observational study is to follow-up and anti-tuberculosis treatment will be provided according to current French recommendations. Participants will provide sociodemographic, clinical, biological, radiological and bacteriological data at various protocol visits at 2 days, 1 and 2 weeks, 2 months, at the end of treatment, 12 and 24 months. Consenting participants will have samples collected at scheduled visits for the establishment of a biobank. This will include blood, urine, breath and hair samples. The positive mycobacterial strains will constitute a specimen bank.",[97],"Tuberculosis",[99,100,101,102,103,104,105,106,107,29,108,109,110,111],"infectious diseases","tuberculosis","clinical","social sciences","public health","Comorbidities","epidemiology","Treatment and care","Transmission","biobank","mycobacterial collection","cohort","prospective","2026-06-10",{"date":114,"type":115},"2026-06-12","ACTUAL",{"date":117,"type":115},"2026-05-06",{"date":119,"type":92},"2031-06",{"name":5,"class":6},2]